Latest News about BHVN
Recent news which mentions BHVN
From Benzinga
From Benzinga
From MarketWatch
From Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
April 27, 2022
From Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
From Benzinga
From Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Insights
February 28, 2022
Tickers
BHVN
From Benzinga
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
February 25, 2022
From Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
From Benzinga
Earnings Scheduled For February 25, 2022
February 25, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
February 14, 2022
From Benzinga
What to Expect From Biogen's $2.3 Billion Shopping Spree
February 12, 2022
From Motley Fool
New Psychedelics ETF Launches On NYSE Arca
February 02, 2022
From Benzinga
Is This a Smart Deal for Pfizer?
January 29, 2022
From Motley Fool
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
January 06, 2022
From Benzinga
Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial
December 06, 2021
Tickers
BHVN
From Benzinga
What 6 Analyst Ratings Have To Say About Biohaven Pharma Hldgs
November 10, 2021
Tickers
BHVN
From Benzinga
75 Biggest Movers From Yesterday
November 10, 2021
From Benzinga
58 Stocks Moving In Monday's Mid-Day Session
November 09, 2021
From Benzinga
From Benzinga
Jim Cramer: MGM Resorts Has Good Top Management
November 09, 2021
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 09, 2021
From Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.